Advertisement
UK markets closed
  • FTSE 100

    8,420.26
    -18.39 (-0.22%)
     
  • FTSE 250

    20,749.90
    -72.94 (-0.35%)
     
  • AIM

    794.02
    +1.52 (+0.19%)
     
  • GBP/EUR

    1.1678
    +0.0023 (+0.20%)
     
  • GBP/USD

    1.2706
    +0.0035 (+0.28%)
     
  • Bitcoin GBP

    52,737.07
    +647.25 (+1.24%)
     
  • CMC Crypto 200

    1,370.89
    -2.95 (-0.21%)
     
  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     
  • DOW

    40,003.59
    +134.21 (+0.34%)
     
  • CRUDE OIL

    80.00
    +0.77 (+0.97%)
     
  • GOLD FUTURES

    2,419.80
    +34.30 (+1.44%)
     
  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     
  • HANG SENG

    19,553.61
    +177.08 (+0.91%)
     
  • DAX

    18,704.42
    -34.39 (-0.18%)
     
  • CAC 40

    8,167.50
    -20.99 (-0.26%)
     

Shield Therapeutics First Half 2023 Earnings: US$0.025 loss per share (vs US$0.069 loss in 1H 2022)

Shield Therapeutics (LON:STX) First Half 2023 Results

Key Financial Results

  • Revenue: US$4.33m (up 69% from 1H 2022).

  • Net loss: US$12.6m (loss narrowed by 16% from 1H 2022).

  • US$0.025 loss per share (improved from US$0.069 loss in 1H 2022).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shield Therapeutics Earnings Insights

Looking ahead, revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Pharmaceuticals industry in the United Kingdom.

Performance of the British Pharmaceuticals industry.

The company's shares are down 32% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Shield Therapeutics (at least 2 which make us uncomfortable), and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.